237 related articles for article (PubMed ID: 6976793)
1. Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
Kessler CM; Klein HG; Havlik RJ
Br J Haematol; 1982 Jan; 50(1):157-67. PubMed ID: 6976793
[TBL] [Abstract][Full Text] [Related]
2. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
3. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
[TBL] [Abstract][Full Text] [Related]
4. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.
Buss DH; Stuart JJ; Lipscomb GE
Am J Hematol; 1985 Dec; 20(4):365-72. PubMed ID: 3865532
[TBL] [Abstract][Full Text] [Related]
5. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
6. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
7. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis.
Jacobsson S; Carneskog J; Ridell B; Wadenvik H; Swolin B; Kutti J
Eur J Haematol; 1996 May; 56(5):287-92. PubMed ID: 8641402
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.
García-Manero G; Schuster SJ; Patrick H; Martinez J
Am J Hematol; 1999 Feb; 60(2):130-5. PubMed ID: 9929105
[TBL] [Abstract][Full Text] [Related]
10. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
13. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Dingli D; Utz JP; Krowka MJ; Oberg AL; Tefferi A
Chest; 2001 Sep; 120(3):801-8. PubMed ID: 11555513
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
17. Bleeding and thrombosis in the myeloproliferative disorders.
Schafer AI
Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
[TBL] [Abstract][Full Text] [Related]
18. Familial myeloproliferative syndrome.
Pérez-Encinas M; Bello JL; Pérez-Crespo S; De Miguel R; Tome S
Am J Hematol; 1994 Jul; 46(3):225-9. PubMed ID: 8192153
[TBL] [Abstract][Full Text] [Related]
19. Secondary gout associated with chronic myeloproliferative disorders.
Yu T; Weinreb N; Wittman R; Wasserman LR
Semin Arthritis Rheum; 1976 Feb; 5(3):247-56. PubMed ID: 1062009
[No Abstract] [Full Text] [Related]
20. Platelet function in patients with high platelet counts.
Ginsburg AD
Ann Intern Med; 1975 Apr; 82(4):506-11. PubMed ID: 1054537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
